Results 81 to 90 of about 4,977 (213)
Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.Background The advent of single‐inhaler triple therapies (SITTs), including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), has expanded treatment options for chronic obstructive pulmonary disease (COPD).
Baiquan Zhang +3 more
wiley +1 more source
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Cost Effectiveness and Resource Allocation, 2018 Background A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).
Zafar Zafari +3 more
doaj +1 more source
Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. [PDF]
, 2016 BackgroundDespite inhaled medications that decrease exacerbation risk, some COPD patients experience frequent exacerbations. We determined prospective risk factors for exacerbations among subjects in the COPDGene Study taking inhaled medications ...
, +8 more
core +4 more sources
Drugs Used in the Treatment of Viral Infections for the Prevention of Airway Remodeling in Asthma
Mediators of Inflammation, Volume 2025, Issue 1, 2025.One of the main causes of the exacerbation of chronic airway inflammatory diseases is respiratory virus infections. The most prevalent viruses that can infect humans multiple times a year are rhinovirus (RV) and respiratory syncytial virus (RSV). Because remodeling factors like matrix metalloproteinases (MMPs), which are released by infiltrating ...
Joanna Wieczfinska +2 more
wiley +1 more source
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study [PDF]
, 2014 Background Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD).
Dave Singh +8 more
core +1 more source
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 7, Issue 12, Page 1207-1227, December 2024.Abstract Cognitive impairment affects around 19% of community‐dwelling older adults in the United States. Pharmacists can play a significant role in identifying and deprescribing cognitive‐impairing medications through cognitive‐focused medication reviews or as part of comprehensive medication management.
Jacob Stanton +4 more
wiley +1 more source
COPD, 2013 Background: This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Jutta Beier +6 more
doaj +1 more source
What can we learn about COPD from impulse oscillometry? [PDF]
, 2018 Impulse oscillometry (IOS) is the most commonly used type of forced oscillation technique in clinical practice, although relatively little is known about its application in COPD.
Jabbal, Sunny, Lipworth, Brian J.
core +2 more sources
Archiv der Pharmazie, Volume 357, Issue 10, October 2024.The role of different substituents in position 2 of 6,6‐diphenyl‐1,4‐dioxane muscarinic receptor ligands in the affinity for the five muscarinic acetylcholine receptor (mAChR) subtypes was studied. The tertiary amine 9 and its eutomer (S)‐(–)‐9 showed picomolar affinity and biphasic curves for all mAChRs.
Gianfabio Giorgioni +10 more
wiley +1 more source
A controlled study of community-based exercise training in patients with moderate COPD. [PDF]
, 2014 BackgroundThe effectiveness of clinic-based pulmonary rehabilitation in advanced COPD is well established, but few data exist for less severe patients treated in alternative settings.
Abrazado, Marlon +5 more
core +2 more sources